Share

Rare But Devastating: Keeping Track of Acromegaly Cases

Since acromegaly is such a rare disorder, when an endocrinologist is presented with a potential case, the most accurate and complete data available would be a helpful tool. Endocrine News takes a closer look at how the Mexican Acromegaly Registry has helped endocrinologists address the issues patients with acromegaly face, both physically and financially.  ...
Share

Progression of Acromegalic Arthropathy Observed in Long-Term Study

Radiographic arthropathy progresses significantly in patients with long-term, well-controlled acromegaly, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Iris C. M. Pelsma, MD, MSc, of Leiden University Medical Center in The Netherlands, point out that one of the long-term complications of acromegaly is acromegalic arthropathy, which...
Share

Phase 3 Trial Data Shows Positive Results for Oral Treatment of Acromegaly

Data presented last month at ENDO 2021 from Phase 3 of the MPOWERED study showed that oral octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. In addition, oral octreotide capsules met the pre-specified non-inferiority margin compared to long-acting iSRLs in maintenance of...
Share

Researchers Determine Best Predictors of Acromegaly Remission Following Transsphenoidal Surgery

Tumor size and random growth hormone concentration at diagnosis are the best predictors for remission of acromegaly after transsphenoidal surgery (TSS), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Eva C. Coopmans, MD, of Erasmus University Medical Center in Rotterdam, The Netherlands, point out that TSS...
Share

Researchers Develop Machine-Learning Prediction Model to Improve Medical Management of Acromegaly

Machine learning (ML), a type of artificial intelligence, could be used to predict how patients with acromegaly respond to first-generation somatostatin receptor ligands (fg-SRLs), according a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Mônica Gadelha, MD, PhD, of the Endocrine Unit and Neuroendocrinology Research Center at the Medical...
Share

New Analysis Finds Cushing’s Syndrome Triples Risk of Death

Heart disease and infections rank as top causes of death among those with rare disorder Endogenous Cushing’s syndrome, a rare hormonal disorder, is associated with a threefold increase in death, primarily due to cardiovascular disease and infection, according to a study presented at ENDO 2021. The research, according to the study authors, is the largest...
Share

From ENDO2021: Phase 3 Trial Results Show Patient Preference for First Oral Therapy for Acromegaly

Data from a Phase 3 trial presented this week at ENDO2021 showed that octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. The data went on to show that 90% of patients receiving octreotide capsules elected to enroll in the open-label extension (OLE)...